应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
已收盘 02-11 16:00:00 EST
220.89
-1.55
-0.70%
盘后
220.68
-0.21
-0.10%
19:58 EST
最高
224.15
最低
218.05
成交量
807.26万
今开
222.27
昨收
222.44
日振幅
2.74%
总市值
3,904亿
流通市值
3,894亿
总股本
17.67亿
成交额
17.83亿
换手率
0.46%
流通股本
17.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期
Minhua笔记 · 02-05
2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期
艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力
美股速递 · 02-04
艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力
艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露
美股速递 · 02-04
艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露
艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局
美股速递 · 02-04
艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局
异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价
异动解读 · 02-04
异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价
艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元
美股速递 · 02-04
艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元
异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价
异动解读 · 02-04
异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价
艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场
美股速递 · 02-04
艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场
医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引
智通财经网 · 02-04
医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引
艾伯维第四季度业绩受收购IPR&D及里程碑费用影响 每股收益承压0.71美元
美股速递 · 02-04
艾伯维第四季度业绩受收购IPR&D及里程碑费用影响 每股收益承压0.71美元
艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物
智通财经 · 02-04
艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物
艾伯维向FDA及EMA提交乌帕替尼治疗成人与青少年白癜风的新适应症申请
美股速递 · 02-03
艾伯维向FDA及EMA提交乌帕替尼治疗成人与青少年白癜风的新适应症申请
艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎
智通财经 · 01-22
艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎
艾伯维高管称伊布替尼将面临竞争与价格谈判带来的市场侵蚀——摩根大通医疗会议
美股速递 · 01-15
艾伯维高管称伊布替尼将面临竞争与价格谈判带来的市场侵蚀——摩根大通医疗会议
艾伯维承诺在美投资千亿美元 以换取关税豁免
智通财经 · 01-13
艾伯维承诺在美投资千亿美元 以换取关税豁免
艾伯维(ABBV.US)承诺在美投资千亿美元 以换取关税豁免
智通财经 · 01-13
艾伯维(ABBV.US)承诺在美投资千亿美元 以换取关税豁免
艾伯维公司未来十年将斥资1000亿美元投入美国研发及资本开支，涵盖制造业
美股速递 · 01-13
艾伯维公司未来十年将斥资1000亿美元投入美国研发及资本开支，涵盖制造业
艾伯维公司：将通过Trumprx平台为医疗补助计划提供低价药品，并扩大面向患者的可负担直接治疗方案
美股速递 · 01-13
艾伯维公司：将通过Trumprx平台为医疗补助计划提供低价药品，并扩大面向患者的可负担直接治疗方案
艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项
美股速递 · 01-12
艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项
艾伯维收购亚利桑那州生产设施，持续强化美国本土制造能力
美股速递 · 01-12
艾伯维收购亚利桑那州生产设施，持续强化美国本土制造能力
加载更多
公司概况
公司名称：
艾伯维公司
所属市场：
NYSE
上市日期：
--
主营业务：
艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格：
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":220.89,"timestamp":1770843600000,"preClose":222.44,"halted":0,"volume":8072609,"hourTrading":{"tag":"盘后","latestPrice":220.68,"preClose":220.89,"latestTime":"19:58 EST","volume":161512,"amount":35676005.6913,"timestamp":1770857930855,"change":-0.21,"changeRate":-0.000951,"amplitude":0.000951},"delay":0,"changeRate":-0.006968171192231664,"floatShares":1762950764,"shares":1767384632,"eps":2.36,"marketStatus":"已收盘","change":-1.55,"latestTime":"02-11 16:00:00 EST","open":222.27,"high":224.15,"low":218.05,"amount":1783048007.2666998,"amplitude":0.027423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.36,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770886800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":222.44,"dividendRate":0.030105,"preHourTrading":{"tag":"盘前","latestPrice":221.7,"preClose":222.44,"latestTime":"09:25 EST","volume":5954,"amount":1323737.45868,"timestamp":1770819940450,"change":-0.74,"changeRate":-0.003327,"amplitude":0.006159},"postHourTrading":{"tag":"盘后","latestPrice":220.68,"preClose":220.89,"latestTime":"19:58 EST","volume":161512,"amount":35676005.6913,"timestamp":1770857930855,"change":-0.21,"changeRate":-0.000951,"amplitude":0.000951},"volumeRatio":0.897097,"impliedVol":0.2876,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2609558780","title":"2025Q4| 艾伯维免疫明星表现不一：乌帕替尼强势增长，利生奇珠单抗未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609558780","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609558780?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:57","pubTimestamp":1770271040,"startTime":"0","endTime":"0","summary":"2月4日，艾伯维公布2025年第四季度及全年业绩，营收和盈利均超预期。公司股价当天下跌约4%，投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元，这主要得益于其重磅药物Humira的出色表现，而其后续免疫学药物Rinvoq强势增长，但Skyrizi的业绩则低于预期。Skyrizi 增长 32.5%，达到 50 亿美元，超过预期的 49 亿美元；Rinvoq 增长 29.5%，达到 23.7 亿美元，但略低于预期。其中，Skyrizi和Rinvoq预计分别贡献约215亿美元和101亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205152126a47f0cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739343.SGD","LU2129689605.HKD","LU2237443549.SGD","LU1718418525.SGD","IE00BGHQF631.EUR","LU1267930573.SGD","LU0912757837.SGD","LU2129689514.USD","LU2237443978.SGD","IE00BSNM7G36.USD","BK4559","IE0004445239.USD","SG9999003800.SGD","SG9999015952.SGD","LU1929549753.HKD","LU1585245621.USD","LU0320765646.SGD","LU0256863902.USD","IE00B19Z3B42.SGD","LU0211327993.USD","ABBV","LU2089283258.USD","SG9999015978.USD","LU1551013342.USD","LU0124676726.USD","LU2347655156.SGD","LU1037948541.HKD","IE00BBT3K403.USD","LU0203345920.USD","LU2237443622.USD","LU2237443895.HKD","LU0256863811.USD","LU0289961442.SGD","LU0310800379.SGD","LU1430594728.SGD","LU0158827948.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU2112291526.USD","LU0861579265.USD","LU1989771016.USD","LU2468319806.SGD","LU0820561818.USD","LU0965509283.SGD","BK4566","BK4585","IE00BJJMRZ35.SGD","LU0511384066.AUD","IE00B3PB1722.GBP","IE0002270589.USD"],"gpt_icon":0},{"id":"1152082663","title":"艾伯维高管预计：2026年及未来数年Skyrizi与Rinvoq将持续面临个位数低价压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1152082663","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152082663?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:32","pubTimestamp":1770219134,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，旗下明星药物Skyrizi（瑞莎珠单抗）与Rinvoq（乌帕替尼）在2026年及后续几年中，预计将持续承受较低的个位数百分比定价阻力。这一预测反映出生物制药行业在医保控费与市场竞争双重压力下的新常态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0158827948.USD","LU0511384066.AUD","LU1162221912.USD","LU0985320562.USD","BK4588","LU0965509283.SGD","LU0820561909.HKD","LU1839511570.USD","LU0795875169.SGD","IE00BLSP4239.USD","LU2129689431.USD","LU2347655156.SGD","LU0949170772.SGD","SG9999011175.SGD","LU0256863902.USD","LU0128525929.USD","LU1989772923.USD","LU2129689605.HKD","LU0708994859.HKD","LU2129689514.USD","LU0211328371.USD","IE00B19Z3581.USD","LU0122379950.USD","LU0472753341.HKD","LU0545039389.USD","IE00BBT3K403.USD","SG9999003800.SGD","LU0912757837.SGD","LU0943347566.SGD","IE00B19Z3B42.SGD","IE0002141913.USD","BK4566","IE00BSNM7G36.USD","LU0689472784.USD","SG9999015986.USD","LU1244550221.USD","LU1585245621.USD","LU2023251221.USD","IE00B42XCP33.USD","LU0965509101.SGD","BK4581","LU0203347892.USD","BK4533","LU0456855351.SGD","LU1003077747.HKD","LU0289739699.SGD","LU1496350171.SGD","BK4139","LU1496350502.SGD","LU0795875086.SGD","BK4534","LU1037948541.HKD","LU1551013425.SGD","LU0057025933.USD","LU0098860793.USD","IE00BN8TJ469.HKD","LU2237443465.HKD","LU0417517546.SGD","IE00BVYPNV92.GBP","LU0689626769.HKD","LU2237443549.SGD","IE00BGHQF631.EUR","LU2237443382.USD","SG9999015978.USD","LU2112291526.USD","LU0211327993.USD","LU1934455194.USD","IE0009355771.USD","IE0004445239.USD","BK4559","LU0234572021.USD","LU0114720955.EUR","LU1093756325.SGD","LU1430594728.SGD","IE00B3PB1722.GBP","LU0310800379.SGD","LU0069063385.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU0124676726.USD","LU1934455277.USD","LU1023059063.AUD","LU0965509010.AUD","LU2089283258.USD","LU0234570918.USD","LU1551013342.USD","LU0738911758.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU0882574055.USD","LU1934455863.HKD","LU0289739343.SGD","LU1989772840.SGD","IE00BDGV0183.EUR","LU0198837287.USD","LU0320765646.SGD","IE00BJJMRZ35.SGD","LU0661504455.SGD","SG9999015952.SGD","LU1291159041.SGD","LU2089284900.SGD","LU1983299246.USD","LU2237443895.HKD","LU1989771016.USD","IE0002270589.USD","LU2237443622.USD","IE00BVYPNW00.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU0310799852.SGD","LU1732800096.USD","IE00B2B36J28.USD","LU1929549753.HKD","LU1244550494.USD","LU1718418525.SGD","LU2237443978.SGD","SG9999001440.SGD","LU1074936037.SGD","LU2133065610.SGD","ABBV","LU0029864427.USD","LU0170899867.USD","LU0553294199.USD","LU1093756168.USD","LU0203345920.USD","LU2087621335.USD","BK4585","LU2468319806.SGD","LU0289961442.SGD","LU2089984988.USD","LU1244550577.SGD","LU1732799900.SGD","LU0058720904.USD","LU0965508806.USD","LU1061106388.HKD","SG9999015945.SGD","LU0820561818.USD","LU1267930573.SGD","LU1267930490.SGD","LU0432979614.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"1128110797","title":"艾伯维高管称公司资金充足，可同时布局早期及后期并购机遇——电话会议透露","url":"https://stock-news.laohu8.com/highlight/detail?id=1128110797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128110797?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:31","pubTimestamp":1770219079,"startTime":"0","endTime":"0","summary":"艾伯维公司高管在最新电话会议中表示，公司目前拥有充足的资金实力，能够同步推进早期阶段与成熟阶段的并购机会。这一表态凸显了艾伯维在生物医药领域持续扩张的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0069063385.USD","IE00BJT1NW94.SGD","LU0965508806.USD","LU2112291526.USD","LU0795875169.SGD","LU0256863902.USD","LU0234570918.USD","LU0310799852.SGD","IE00BSNM7G36.USD","LU1162221912.USD","LU1551013425.SGD","LU1718418525.SGD","LU0553294199.USD","LU0128525929.USD","IE00BDGV0183.EUR","LU1585245621.USD","LU1929549753.HKD","SG9999011175.SGD","LU0320765646.SGD","IE0004445239.USD","LU1244550494.USD","LU0198837287.USD","LU0795875086.SGD","LU2023251221.USD","IE00BLSP4239.USD","LU0158827948.USD","BK4534","LU0965509283.SGD","LU0949170772.SGD","LU1430594728.SGD","LU1267930490.SGD","LU1496350502.SGD","LU1983299246.USD","LU2237443382.USD","LU1989772840.SGD","IE00B19Z3B42.SGD","IE0002141913.USD","LU0098860793.USD","LU2237443895.HKD","IE00B2B36J28.USD","LU0417517546.SGD","LU1989771016.USD","LU0029864427.USD","LU1003077747.HKD","SG9999001440.SGD","LU0114720955.EUR","LU1023059063.AUD","SG9999015986.USD","LU0820561909.HKD","IE00BJJMRZ35.SGD","BK4588","LU1093756168.USD","LU1934455863.HKD","LU0965509010.AUD","LU2129689514.USD","LU1061106388.HKD","LU1732799900.SGD","LU0289739699.SGD","LU0820561818.USD","IE00B19Z3581.USD","LU0689626769.HKD","BK4559","IE00B42XCP33.USD","IE00BGHQF631.EUR","LU0511384066.AUD","SG9999015952.SGD","LU1291159041.SGD","LU0256863811.USD","BK4550","LU1267930573.SGD","SG9999003800.SGD","LU0170899867.USD","BK4566","LU2129689605.HKD","LU1074936037.SGD","LU2237443549.SGD","IE00BVYPNW00.USD","IE00BLSP4452.SGD","LU0965509101.SGD","LU2237443978.SGD","LU0472753341.HKD","LU0289961442.SGD","LU0289739343.SGD","SG9999015978.USD","LU2129689431.USD","LU0432979614.USD","LU0689472784.USD","LU0211327993.USD","IE00B4R5TH58.HKD","LU0861579265.USD","LU1037948541.HKD","LU1244550577.SGD","BK4533","LU0943347566.SGD","LU0738911758.USD","SG9999015945.SGD","LU0058720904.USD","LU0203345920.USD","LU2237443622.USD","LU0882574055.USD","BK4585","LU2089283258.USD","LU1496350171.SGD","IE00BN8TJ469.HKD","LU1934455194.USD","LU0122379950.USD","LU2089984988.USD","LU0456855351.SGD","ABBV","LU0985320562.USD","IE0002270589.USD","LU2087621335.USD","LU0124676726.USD","LU1037948897.HKD","LU2133065610.SGD","LU1057294990.SGD","LU0310800379.SGD","IE00B3PB1722.GBP","BK4581","LU0234572021.USD","LU0211328371.USD","LU1093756325.SGD","LU0912757837.SGD","BK4139","LU1934455277.USD","LU0545039389.USD","IE0009355771.USD","IE00BBT3K403.USD","LU0203347892.USD","LU1551013342.USD","IE00BVYPNV92.GBP","LU0708994859.HKD","LU1732800096.USD","LU1839511570.USD","LU2089284900.SGD","LU0661504455.SGD","LU2237443465.HKD","LU0057025933.USD","LU2468319806.SGD","LU1989772923.USD","LU1244550221.USD","IE00BFTCPJ56.SGD","LU2347655156.SGD"],"gpt_icon":0},{"id":"1138286335","title":"艾伯维高管称潜在交易不限于早期阶段，聚焦核心领域：免疫学、神经科学、肿瘤学及肥胖症布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1138286335","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138286335?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:30","pubTimestamp":1770219013,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，公司在寻求潜在交易时不会局限于早期阶段项目，而是将战略重点集中于核心业务领域。这些关键领域包括免疫学、神经科学、肿瘤学，以及正在积极拓展的肥胖症治疗方向。公司旨在通过多元化的合作方式强化产品管线，推动长期增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU1551013342.USD","LU0203345920.USD","LU0310800379.SGD","LU1057294990.SGD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU1496350502.SGD","LU0511384066.AUD","LU1934455863.HKD","IE00B42XCP33.USD","LU1934455194.USD","SG9999015986.USD","LU0417517546.SGD","BK4588","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1244550221.USD","LU0289739699.SGD","LU1929549753.HKD","LU0943347566.SGD","LU1989771016.USD","SG9999015978.USD","LU0708994859.HKD","LU0029864427.USD","LU0965509010.AUD","IE00BVYPNW00.USD","LU0124676726.USD","LU0289739343.SGD","LU1934455277.USD","LU0965509101.SGD","LU1162221912.USD","SG9999003800.SGD","LU0069063385.USD","LU0949170772.SGD","LU0795875086.SGD","LU0861579265.USD","LU2112291526.USD","BK4139","LU2023251221.USD","LU0256863811.USD","SG9999015945.SGD","LU0795875169.SGD","LU2089984988.USD","LU2237443382.USD","IE00BVYPNV92.GBP","LU0310799852.SGD","IE00BGHQF631.EUR","LU0198837287.USD","LU1074936037.SGD","LU1244550577.SGD","LU0289961442.SGD","LU1037948541.HKD","LU1061106388.HKD","SG9999015952.SGD","LU0882574055.USD","LU1732800096.USD","LU1003077747.HKD","LU2237443549.SGD","IE00B19Z3581.USD","LU1989772840.SGD","LU2468319806.SGD","IE0002141913.USD","LU1023059063.AUD","BK4550","ABBV","IE00BFTCPJ56.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","BK4585","LU2089284900.SGD","LU0234570918.USD","LU0320765646.SGD","IE0009355771.USD","LU0170899867.USD","LU0661504455.SGD","LU0965509283.SGD","IE0002270589.USD","LU1244550494.USD","LU2129689431.USD","LU2237443895.HKD","LU0820561909.HKD","LU0472753341.HKD","LU2237443622.USD","LU0738911758.USD","LU1430594728.SGD","BK4533","LU0432979614.USD","LU1551013425.SGD","LU0689472784.USD","BK4559","LU1267930573.SGD","LU0211328371.USD","LU1585245621.USD","LU1839511570.USD","LU2133065610.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","LU1037948897.HKD","BK4581","LU0912757837.SGD","LU0456855351.SGD","LU0234572021.USD","LU1989772923.USD","BK4534","LU0211327993.USD","LU2129689514.USD","IE00B4R5TH58.HKD","LU2089283258.USD","LU0553294199.USD","LU0545039389.USD","LU0128525929.USD","LU0122379950.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU1093756168.USD","LU0058720904.USD","LU2087621335.USD","LU0256863902.USD","LU1732799900.SGD","IE00B19Z3B42.SGD","LU1291159041.SGD","SG9999011175.SGD","LU1093756325.SGD","LU2237443465.HKD","IE00BBT3K403.USD","LU2237443978.SGD","LU2347655156.SGD","LU0965508806.USD","LU0820561818.USD","LU0203347892.USD","IE00BN8TJ469.HKD","LU0985320562.USD","IE00BLSP4239.USD","LU1983299246.USD","IE0004445239.USD","LU1496350171.SGD","LU1267930490.SGD","BK4566","LU0158827948.USD","LU0689626769.HKD","LU0098860793.USD"],"gpt_icon":0},{"id":"1186940641","title":"异动解读 | 艾伯维盘中大跌7.25%，营收结构担忧、医美业务承压及一次性费用拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186940641","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186940641?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:41","pubTimestamp":1770216062,"startTime":"0","endTime":"0","summary":"艾伯维（ABBV）今日盘中股价大幅下跌7.25%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发了市场对营收结构可持续性的担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司最新公布的第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，这些一次性支出对每股收益造成了0.71美元的负面影响。市场对上述因素的叠加反应，共同导致了此次股价的大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"gpt_icon":0},{"id":"1135576917","title":"艾伯维高管预计：2026年Skyrizi收入将达215亿美元，Rinvoq收入将达101亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135576917","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135576917?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:36","pubTimestamp":1770215794,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日透露，预计到2026年，其明星产品Skyrizi的年收入将攀升至215亿美元，而同为重磅药物的Rinvoq也将实现101亿美元的营收目标。这一预测凸显了公司对这两款免疫疾病治疗药物市场前景的强烈信心。\n随着全球自身免疫疾病患者群体的持续扩大，Skyrizi和Rinvoq凭借卓越的临床疗效，正逐步成为细分领域的领军产品。分析指出，若能达到预期目标，这两款药物将共同构筑艾伯维未来业绩增长的双引擎，有效抵消明星修美乐专利到期后带来的收入压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089283258.USD","LU1551013342.USD","BK4585","LU1732799900.SGD","IE00B42XCP33.USD","LU1496350171.SGD","BK4559","LU1057294990.SGD","LU0289961442.SGD","LU0820561909.HKD","IE00B19Z3581.USD","LU0943347566.SGD","LU1929549753.HKD","LU0545039389.USD","LU2237443465.HKD","ABBV","LU0965509101.SGD","LU1934455863.HKD","LU0472753341.HKD","LU2129689431.USD","BK4581","LU1718418525.SGD","LU2237443895.HKD","SG9999001440.SGD","LU0320765646.SGD","LU0820561818.USD","LU0058720904.USD","BK4588","LU0124676726.USD","LU1430594728.SGD","LU1732800096.USD","LU1496350502.SGD","LU1093756168.USD","LU0029864427.USD","LU0310800379.SGD","LU2237443978.SGD","IE00BGHQF631.EUR","LU1267930573.SGD","LU0738911758.USD","LU0965509010.AUD","BK4534","BK4139","LU1162221912.USD","BK4550","LU2129689605.HKD","LU0114720955.EUR","LU2237443622.USD","IE00BFTCPJ56.SGD","LU0098860793.USD","LU1244550221.USD","SG9999015986.USD","LU0203345920.USD","LU0158827948.USD","LU0234570918.USD","LU1989772840.SGD","LU0310799852.SGD","LU0289739343.SGD","LU1244550577.SGD","LU0861579265.USD","IE0002141913.USD","LU0708994859.HKD","LU0689472784.USD","LU0211327993.USD","LU1023059063.AUD","IE00BVYPNV92.GBP","IE00B3PB1722.GBP","LU0432979614.USD","SG9999003800.SGD","IE00BJT1NW94.SGD","LU0795875086.SGD","LU1989772923.USD","LU0965509283.SGD","LU1989771016.USD","LU1839511570.USD","LU0198837287.USD","IE00BLSP4452.SGD","LU0203347892.USD","IE00BN8TJ469.HKD","LU2023251221.USD","IE00BDGV0183.EUR","LU1267930490.SGD","LU2089984988.USD","IE00BVYPNW00.USD","IE00B4R5TH58.HKD","LU2112291526.USD","LU0234572021.USD","LU0965508806.USD","LU0256863902.USD","LU1551013425.SGD","LU1934455194.USD","LU0912757837.SGD","LU1983299246.USD","LU2129689514.USD","LU0689626769.HKD","LU0882574055.USD","LU0456855351.SGD","LU1074936037.SGD","LU0949170772.SGD","LU0170899867.USD","LU0795875169.SGD","IE00BJJMRZ35.SGD","BK4533","IE0009355771.USD","IE00BSNM7G36.USD","LU0553294199.USD","LU0128525929.USD","LU2347655156.SGD","IE00BBT3K403.USD","LU0256863811.USD","LU2468319806.SGD","LU1244550494.USD","IE00BLSP4239.USD","LU2133065610.SGD","LU1934455277.USD","LU1291159041.SGD","LU1037948897.HKD","IE00B2B36J28.USD","LU1585245621.USD","LU0122379950.USD","LU0069063385.USD","IE00B19Z3B42.SGD","IE0004445239.USD","LU0289739699.SGD","LU1061106388.HKD","LU2087621335.USD","LU0057025933.USD","LU0211328371.USD","LU1003077747.HKD","SG9999015952.SGD","LU0985320562.USD","LU2237443382.USD","LU2089284900.SGD","LU1037948541.HKD","SG9999015978.USD","LU1093756325.SGD","BK4566","LU0661504455.SGD","SG9999015945.SGD","IE0002270589.USD","LU2237443549.SGD","SG9999011175.SGD","LU0511384066.AUD","LU0417517546.SGD"],"gpt_icon":0},{"id":"1170942267","title":"异动解读 | 艾伯维盘前大跌6.5%，营收增长依赖传统药物及医美业务承压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1170942267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170942267?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:27","pubTimestamp":1770215246,"startTime":"0","endTime":"0","summary":"艾伯维公司（ABBV）今日盘前股价大幅下跌6.50%，引发了市场广泛关注。消息面上，尽管公司预测2026年利润高于预期，但分析师指出其营收增长主要依赖传统药物Humira，而该药销售额正受到仿制药侵蚀，引发市场担忧。同时，公司高管预计2026年医美业务增长仍将面临挑战，需通过投资刺激渗透率偏低的市场。此外，公司第四季度业绩受到收购相关无形资产研发及里程碑费用的显著拖累，对每股收益造成0.71美元的负面影响。综合来看，市场对艾伯维营收结构可持续性的疑虑、部分业务增长压力以及短期业绩受一次性费用拖累，共同导致了此次股价的大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"gpt_icon":0},{"id":"1154893154","title":"艾伯维高管预计2026年医美业务增长仍将承压 将重点投资刺激渗透率偏低市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1154893154","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154893154?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:23","pubTimestamp":1770214996,"startTime":"0","endTime":"0","summary":"艾伯维公司高管近日表示，预计到2026年其医美业务增长仍将面临挑战。公司正集中资源通过战略性投资来激活当前渗透率严重不足的市场。\n该高管指出，尽管面临短期增长压力，但医美市场仍存在巨大发展空间。公司将持续投入资金用于市场培育，通过创新营销策略和渠道拓展来挖掘潜在需求。\n目前全球医美市场的渗透水平仍处于低位，这既是挑战也是机遇。艾伯维将把投资重点放在提升市场认知度和可及性上，以期在未来实现业务突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU1551013342.USD","LU0203345920.USD","LU0310800379.SGD","LU1057294990.SGD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU1496350502.SGD","LU0511384066.AUD","LU1934455863.HKD","IE00B42XCP33.USD","LU1934455194.USD","SG9999015986.USD","LU0417517546.SGD","BK4588","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1244550221.USD","LU0289739699.SGD","LU1929549753.HKD","LU0943347566.SGD","LU1989771016.USD","SG9999015978.USD","LU0708994859.HKD","LU0029864427.USD","LU0965509010.AUD","IE00BVYPNW00.USD","LU0124676726.USD","LU0289739343.SGD","LU1934455277.USD","LU0965509101.SGD","LU1162221912.USD","SG9999003800.SGD","LU0069063385.USD","LU0949170772.SGD","LU0795875086.SGD","LU0861579265.USD","LU2112291526.USD","BK4139","LU2023251221.USD","LU0256863811.USD","SG9999015945.SGD","LU0795875169.SGD","LU2089984988.USD","LU2237443382.USD","IE00BVYPNV92.GBP","LU0310799852.SGD","IE00BGHQF631.EUR","LU0198837287.USD","LU1074936037.SGD","LU1244550577.SGD","LU0289961442.SGD","LU1037948541.HKD","LU1061106388.HKD","SG9999015952.SGD","LU0882574055.USD","LU1732800096.USD","LU1003077747.HKD","LU2237443549.SGD","IE00B19Z3581.USD","LU1989772840.SGD","LU2468319806.SGD","IE0002141913.USD","LU1023059063.AUD","BK4550","ABBV","IE00BFTCPJ56.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","BK4585","LU2089284900.SGD","LU0234570918.USD","LU0320765646.SGD","IE0009355771.USD","LU0170899867.USD","LU0661504455.SGD","LU0965509283.SGD","IE0002270589.USD","LU1244550494.USD","LU2129689431.USD","LU2237443895.HKD","LU0820561909.HKD","LU0472753341.HKD","LU2237443622.USD","LU0738911758.USD","LU1430594728.SGD","BK4533","LU0432979614.USD","LU1551013425.SGD","LU0689472784.USD","BK4559","LU1267930573.SGD","LU0211328371.USD","LU1585245621.USD","LU1839511570.USD","LU2133065610.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","LU1037948897.HKD","BK4581","LU0912757837.SGD","LU0456855351.SGD","LU0234572021.USD","LU1989772923.USD","BK4534","LU0211327993.USD","LU2129689514.USD","IE00B4R5TH58.HKD","LU2089283258.USD","LU0553294199.USD","LU0545039389.USD","LU0128525929.USD","LU0122379950.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU1093756168.USD","LU0058720904.USD","LU2087621335.USD","LU0256863902.USD","LU1732799900.SGD","IE00B19Z3B42.SGD","LU1291159041.SGD","SG9999011175.SGD","LU1093756325.SGD","LU2237443465.HKD","IE00BBT3K403.USD","LU2237443978.SGD","LU2347655156.SGD","LU0965508806.USD","LU0820561818.USD","LU0203347892.USD","IE00BN8TJ469.HKD","LU0985320562.USD","IE00BLSP4239.USD","LU1983299246.USD","IE0004445239.USD","LU1496350171.SGD","LU1267930490.SGD","BK4566","LU0158827948.USD","LU0689626769.HKD","LU0098860793.USD"],"gpt_icon":0},{"id":"2608362477","title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362477","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362477?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:33","pubTimestamp":1770212037,"startTime":"0","endTime":"0","summary":"由于为提振低迷医美业务所做的一系列举措开始见效，艾伯维周三公布了超预期的第四季度业绩，同时上调了2026年盈利指引。","market":"sg","thumbnail":"https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6a8642475395bb363eacb86148917e7b"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401765.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"医美业务复苏！艾伯维Q4财报超预期，同步上调全年利润指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ABBV"],"gpt_icon":0},{"id":"1151308318","title":"艾伯维第四季度业绩受收购IPR&D及里程碑费用影响 每股收益承压0.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151308318","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151308318?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:49","pubTimestamp":1770209352,"startTime":"0","endTime":"0","summary":"艾伯维最新公布的第四季度财务数据显示，公司当季业绩受到收购相关无形资产研发（IPR&D）及里程碑费用的显著拖累。具体而言，这些一次性支出对每股收益造成了0.71美元的负面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","IE00BDGV0183.EUR","BK4139","LU0985320562.USD","LU1989772923.USD","LU2237443622.USD","LU1430594728.SGD","BK4566","LU1839511570.USD","LU0912757837.SGD","SG9999001440.SGD","LU1732800096.USD","IE00BVYPNV92.GBP","LU0320765646.SGD","IE0002141913.USD","LU0122379950.USD","LU0211327993.USD","LU2089283258.USD","LU0256863902.USD","LU0965509101.SGD","LU2112291526.USD","LU0965509283.SGD","LU0553294199.USD","LU0289961442.SGD","BK4534","LU1093756168.USD","LU0432979614.USD","LU0472753341.HKD","LU0708994859.HKD","LU0289739699.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","LU0965508806.USD","LU0882574055.USD","LU1061106388.HKD","LU0069063385.USD","LU1023059063.AUD","LU1585245621.USD","LU2347655156.SGD","SG9999015945.SGD","LU0310800379.SGD","LU2129689605.HKD","IE0002270589.USD","LU1057294990.SGD","LU0738911758.USD","IE00BN8TJ469.HKD","BK4550","LU1267930490.SGD","IE0004445239.USD","IE00B3PB1722.GBP","LU1934455194.USD","LU1093756325.SGD","LU2129689431.USD","LU1983299246.USD","BK4581","LU0098860793.USD","IE00BBT3K403.USD","BK4533","IE00B2B36J28.USD","LU0289739343.SGD","LU0943347566.SGD","IE0009355771.USD","IE00B42XCP33.USD","LU1934455277.USD","LU0661504455.SGD","LU2237443895.HKD","LU2129689514.USD","LU0965509010.AUD","LU2133065610.SGD","LU0198837287.USD","LU2087621335.USD","LU1003077747.HKD","LU0234570918.USD","LU0124676726.USD","SG9999015986.USD","LU0820561909.HKD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU0029864427.USD","LU1929549753.HKD","LU0211328371.USD","LU2237443382.USD","LU1244550577.SGD","LU0820561818.USD","BK4588","LU1037948541.HKD","LU1074936037.SGD","LU1934455863.HKD","LU0203345920.USD","SG9999015952.SGD","LU1244550494.USD","LU2237443549.SGD","LU1291159041.SGD","LU1732799900.SGD","LU1989772840.SGD","LU0511384066.AUD","SG9999011175.SGD","SG9999003800.SGD","LU1989771016.USD","LU0310799852.SGD","LU0456855351.SGD","LU2023251221.USD","IE00BLSP4452.SGD","BK4559","IE00BSNM7G36.USD","LU1267930573.SGD","LU0795875169.SGD","LU1496350171.SGD","LU2237443465.HKD","ABBV","IE00BGHQF631.EUR","LU0861579265.USD","LU1551013425.SGD","LU0203347892.USD","LU1496350502.SGD","IE00B19Z3B42.SGD","LU2468319806.SGD","BK4585","LU0057025933.USD","LU0158827948.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU2089284900.SGD","LU0417517546.SGD","LU0689472784.USD","LU2089984988.USD","LU2237443978.SGD","LU0795875086.SGD","IE00BVYPNW00.USD","LU1244550221.USD","SG9999015978.USD","LU1162221912.USD","IE00BLSP4239.USD","LU0170899867.USD","LU0949170772.SGD","LU1551013342.USD","LU0689626769.HKD","LU0128525929.USD","LU0545039389.USD","LU1718418525.SGD","LU0114720955.EUR","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2608733028","title":"艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2608733028","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608733028?lang=zh_cn&edition=full","pubTime":"2026-02-04 14:48","pubTimestamp":1770187724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，当地时间2月3日，艾伯维宣布，已向美国 FDA 和欧洲 EMA 提交了乌帕替尼用于治疗成人和青少年非节段型白癜风的新适应症申请。若获得批准，乌帕替尼将成为首个可用于治疗白癜风的全身性药物，以期改变白癜风的治疗格局。此前公布的 Viti-Up 研究结果支持了此次向FDA和EMA提交的监管申请。据悉，乌帕替尼为艾伯维旗下的重磅产品，2024年全球销售额为59.71亿美元，同比增长50.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)乌帕替尼新适应症申报上市 或将成为首个用于治疗白癜风的全身性药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2087621335.USD","LU1244550494.USD","LU0708994859.HKD","LU1267930573.SGD","IE00B4R5TH58.HKD","LU0170899867.USD","IE00BLSP4239.USD","SG9999001440.SGD","LU0256863811.USD","LU0912757837.SGD","LU2237443382.USD","LU1061106388.HKD","LU0965509283.SGD","BK4581","LU0965508806.USD","LU1718418525.SGD","LU1551013342.USD","LU2237443465.HKD","IE00B19Z3581.USD","LU2089283258.USD","LU0289739699.SGD","BK4566","LU0158827948.USD","BK4533","LU1551013425.SGD","LU0310799852.SGD","LU2129689514.USD","IE00BBT3K403.USD","LU1934455277.USD","SG9999015986.USD","LU2237443622.USD","LU2237443549.SGD","LU2237443895.HKD","BK4550","LU1162221912.USD","LU0122379950.USD","LU0943347566.SGD","ABBV","LU1732800096.USD","LU0738911758.USD","IE00B19Z3B42.SGD","BK4559","LU0882574055.USD","LU1023059063.AUD","LU0320765646.SGD","LU0114720955.EUR","BK4588","LU1934455194.USD","BK4534","LU1093756168.USD"],"gpt_icon":0},{"id":"1155170461","title":"艾伯维向FDA及EMA提交乌帕替尼治疗成人与青少年白癜风的新适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1155170461","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155170461?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:00","pubTimestamp":1770123615,"startTime":"0","endTime":"0","summary":"艾伯维公司已正式向美国食品药品监督管理局（FDA）及欧洲药品管理局（EMA）提交了乌帕替尼（商品名：Rinvoq®）用于治疗成人与青少年白癜风患者的监管申请。此次提交标志着该JAK抑制剂在拓展自身免疫疾病治疗版图上的重要进展。若获批准，乌帕替尼将成为针对这一慢性皮肤病患者群体的创新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","LU1551013342.USD","LU0203345920.USD","LU0310800379.SGD","LU1057294990.SGD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU1496350502.SGD","LU0511384066.AUD","LU1934455863.HKD","IE00B42XCP33.USD","LU1934455194.USD","SG9999015986.USD","LU0417517546.SGD","BK4588","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1244550221.USD","LU0289739699.SGD","LU1929549753.HKD","LU0943347566.SGD","LU1989771016.USD","SG9999015978.USD","LU0708994859.HKD","LU0029864427.USD","LU0965509010.AUD","IE00BVYPNW00.USD","LU0124676726.USD","LU0289739343.SGD","LU1934455277.USD","LU0965509101.SGD","LU1162221912.USD","SG9999003800.SGD","LU0069063385.USD","LU0949170772.SGD","LU0795875086.SGD","LU0861579265.USD","LU2112291526.USD","BK4139","LU2023251221.USD","LU0256863811.USD","SG9999015945.SGD","LU0795875169.SGD","LU2089984988.USD","LU2237443382.USD","IE00BVYPNV92.GBP","LU0310799852.SGD","IE00BGHQF631.EUR","LU0198837287.USD","LU1074936037.SGD","LU1244550577.SGD","LU0289961442.SGD","LU1037948541.HKD","LU1061106388.HKD","SG9999015952.SGD","LU0882574055.USD","LU1732800096.USD","LU1003077747.HKD","LU2237443549.SGD","IE00B19Z3581.USD","LU1989772840.SGD","LU2468319806.SGD","IE0002141913.USD","LU1023059063.AUD","BK4550","ABBV","IE00BFTCPJ56.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","BK4585","LU2089284900.SGD","LU0234570918.USD","LU0320765646.SGD","IE0009355771.USD","LU0170899867.USD","LU0661504455.SGD","LU0965509283.SGD","IE0002270589.USD","LU1244550494.USD","LU2129689431.USD","LU2237443895.HKD","LU0820561909.HKD","LU0472753341.HKD","LU2237443622.USD","LU0738911758.USD","LU1430594728.SGD","BK4533","LU0432979614.USD","LU1551013425.SGD","LU0689472784.USD","BK4559","LU1267930573.SGD","LU0211328371.USD","LU1585245621.USD","LU1839511570.USD","LU2133065610.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","LU1037948897.HKD","BK4581","LU0912757837.SGD","LU0456855351.SGD","LU0234572021.USD","LU1989772923.USD","BK4534","LU0211327993.USD","LU2129689514.USD","IE00B4R5TH58.HKD","LU2089283258.USD","LU0553294199.USD","LU0545039389.USD","LU0128525929.USD","LU0122379950.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU1093756168.USD","LU0058720904.USD","LU2087621335.USD","LU0256863902.USD","LU1732799900.SGD","IE00B19Z3B42.SGD","LU1291159041.SGD","SG9999011175.SGD","LU1093756325.SGD","LU2237443465.HKD","IE00BBT3K403.USD","LU2237443978.SGD","LU2347655156.SGD","LU0965508806.USD","LU0820561818.USD","LU0203347892.USD","IE00BN8TJ469.HKD","LU0985320562.USD","IE00BLSP4239.USD","LU1983299246.USD","IE0004445239.USD","LU1496350171.SGD","LU1267930490.SGD","BK4566","LU0158827948.USD","LU0689626769.HKD","LU0098860793.USD"],"gpt_icon":0},{"id":"2605145750","title":"艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145750","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605145750?lang=zh_cn&edition=full","pubTime":"2026-01-22 14:31","pubTimestamp":1769063499,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，艾伯维宣布利生奇珠单抗在华获批第二项适应症，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性溃疡性结肠炎成年患者。IL-23是一种参与炎症过程的细胞因子，被认为与许多慢性免疫介导疾病有关。2025年3月10日，利生奇珠单抗在中国首次获批上市，用于治疗对传统治疗或生物制剂治疗应答不足、失应答或不耐受的中重度活动性克罗恩病成年患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"艾伯维(ABBV.US)利生奇珠单抗新适应症在华获批 用于治疗溃疡性结肠炎","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","LU0795875169.SGD","LU0965509101.SGD","LU1093756168.USD","LU1430594728.SGD","LU0708994859.HKD","LU1496350171.SGD","LU0795875086.SGD","IE00BJJMRZ35.SGD","BK4550","SG9999011175.SGD","LU1057294990.SGD","LU1839511570.USD","SG9999001440.SGD","BK4566","LU1718418525.SGD","BK4559","LU1037948541.HKD","LU1074936037.SGD","LU2089283258.USD","IE00B19Z3581.USD","LU0211327993.USD","LU1061106388.HKD","LU1551013342.USD","LU2133065610.SGD","ABBV","LU0114720955.EUR","LU0965509283.SGD","LU2468319806.SGD","LU0820561909.HKD","LU2023251221.USD","LU0029864427.USD","IE00BVYPNW00.USD","LU1003077747.HKD","LU1496350502.SGD","LU2089984988.USD","LU0310800379.SGD","SG9999015952.SGD","IE00BVYPNV92.GBP","LU0965509010.AUD","LU0158827948.USD","LU2237443895.HKD","BK4581","LU0545039389.USD","LU0320765646.SGD","LU0289739343.SGD","LU0912757837.SGD","LU1732800096.USD","LU2237443465.HKD","LU0689472784.USD"],"gpt_icon":0},{"id":"1194878871","title":"艾伯维高管称伊布替尼将面临竞争与价格谈判带来的市场侵蚀——摩根大通医疗会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1194878871","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194878871?lang=zh_cn&edition=full","pubTime":"2026-01-15 01:16","pubTimestamp":1768410985,"startTime":"0","endTime":"0","summary":"在摩根大通医疗健康大会上，艾伯维公司高管坦言，旗下重磅药物伊布替尼（Imbruvica）未来将因市场竞争加剧及医保价格谈判压力，出现一定程度的市场份额侵蚀。\n这一表态反映出生物医药行业当前面临的共同挑战：明星产品在专利保护期后面临仿制药竞争，同时全球范围内医保控费政策日趋严格，企业需在创新投入与利润平衡间寻求新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","LU0128525929.USD","IE00B3PB1722.GBP","LU2089984988.USD","BK4559","LU1983299246.USD","LU1267930490.SGD","LU2237443895.HKD","BK4533","LU1244550494.USD","LU1267930573.SGD","LU2347655156.SGD","LU2468319806.SGD","IE00B42XCP33.USD","IE00BVYPNW00.USD","LU2133065610.SGD","LU2129689605.HKD","SG9999015986.USD","BK4139","LU1989772840.SGD","BK4550","LU1934455277.USD","IE00BLSP4452.SGD","LU1551013342.USD","SG9999015952.SGD","LU1162221912.USD","LU0965509283.SGD","LU0234572021.USD","SG9999015978.USD","LU0820561818.USD","LU1244550577.SGD","LU0057025933.USD","LU0234570918.USD","LU0985320562.USD","LU1244550221.USD","IE00BGHQF631.EUR","BK4566","LU1074936037.SGD","LU1718418525.SGD","IE00BDGV0183.EUR","LU0553294199.USD","IE00B19Z3581.USD","LU1093756168.USD","LU0965509101.SGD","LU1839511570.USD","ABBV","IE00BJJMRZ35.SGD","LU0122379950.USD","LU2112291526.USD","IE0009355771.USD","LU0170899867.USD","LU1934455863.HKD","LU0861579265.USD","LU1989771016.USD","LU0256863811.USD","LU0098860793.USD","LU0912757837.SGD","IE00B19Z3B42.SGD","LU0949170772.SGD","LU1585245621.USD","LU0456855351.SGD","LU0058720904.USD","LU0320765646.SGD","LU1061106388.HKD","LU1093756325.SGD","LU0114720955.EUR","LU1037948541.HKD","LU1003077747.HKD","LU0661504455.SGD","LU2089283258.USD","LU0432979614.USD","LU0211327993.USD","LU0943347566.SGD","LU0289739699.SGD","LU2129689514.USD","LU1057294990.SGD","LU0310799852.SGD","LU2089284900.SGD","IE00BSNM7G36.USD","IE0002270589.USD","SG9999015945.SGD","LU2237443622.USD","BK4534","LU0158827948.USD","IE00BJT1NW94.SGD","IE00BVYPNV92.GBP","LU0069063385.USD","LU0289739343.SGD","SG9999003800.SGD","LU1732800096.USD","LU1989772923.USD","LU0203347892.USD","LU2087621335.USD","LU2237443382.USD","LU2237443549.SGD","LU0965509010.AUD","LU1037948897.HKD","BK4588","LU1551013425.SGD","BK4581","LU0472753341.HKD","LU0689626769.HKD","LU2237443978.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU2237443465.HKD","LU1291159041.SGD","BK4585","LU1430594728.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1496350502.SGD","IE0002141913.USD","IE00BN8TJ469.HKD","LU0256863902.USD","LU0310800379.SGD","LU0511384066.AUD","LU0965508806.USD","LU0203345920.USD","LU0198837287.USD","LU1496350171.SGD","LU2023251221.USD","LU0795875169.SGD","LU0708994859.HKD","LU1934455194.USD","LU0882574055.USD","LU0417517546.SGD","SG9999001440.SGD","LU2129689431.USD","IE0004445239.USD","IE00BLSP4239.USD","LU1023059063.AUD","LU0211328371.USD","LU0689472784.USD","IE00B4R5TH58.HKD","LU0289961442.SGD","LU0820561909.HKD","LU0545039389.USD","LU1732799900.SGD","LU0795875086.SGD","LU0029864427.USD","LU0738911758.USD","LU0124676726.USD"],"gpt_icon":0},{"id":"1192910344","title":"艾伯维承诺在美投资千亿美元 以换取关税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=1192910344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192910344?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:49","pubTimestamp":1768276177,"startTime":"0","endTime":"0","summary":"艾伯维近日与美国政府签署协议，承诺下调部分药品价格并在美本土投资1000亿美元，以换取特定关税豁免资格。艾伯维在周一发布的声明中表示，本次签署的协议全面响应了上述四项要求。根据协议，未来十年内，艾伯维将把这1000亿美元投向美国本土的研发领域及资本开支项目，其中涵盖药品生产制造环节。作为交换条件，艾伯维将获得关税豁免资格，同时免于受到未来药品定价强制政策的约束。","market":"us","thumbnail":"https://static.tigerbbs.com/819399b2009bd809953aeb10f7e13fae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/819399b2009bd809953aeb10f7e13fae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1392071.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ABBV"],"gpt_icon":0},{"id":"2603579765","title":"艾伯维(ABBV.US)承诺在美投资千亿美元 以换取关税豁免","url":"https://stock-news.laohu8.com/highlight/detail?id=2603579765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603579765?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:26","pubTimestamp":1768274813,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维近日与美国政府签署协议，承诺下调部分药品价格并在美本土投资1000亿美元，以换取特定关税豁免资格。艾伯维在周一发布的声明中表示，本次签署的协议全面响应了上述四项要求。根据协议，未来十年内，艾伯维将把这1000亿美元投向美国本土的研发领域及资本开支项目，其中涵盖药品生产制造环节。作为交换条件，艾伯维将获得关税豁免资格，同时免于受到未来药品定价强制政策的约束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015945.SGD","LU2237443622.USD","LU1496350171.SGD","LU2347655156.SGD","LU1718418525.SGD","LU2129689431.USD","LU2089984988.USD","LU0211327993.USD","LU2237443978.SGD","IE00B42XCP33.USD","IE00BLSP4239.USD","LU0912757837.SGD","IE00BBT3K403.USD","LU0965509010.AUD","LU0965509101.SGD","IE00BSNM7G36.USD","LU1037948541.HKD","LU1267930573.SGD","LU1934455863.HKD","LU0158827948.USD","LU0310799852.SGD","LU1162221912.USD","IE00BVYPNV92.GBP","ABBV","LU1023059063.AUD","LU1244550577.SGD","LU2089284900.SGD","LU1732800096.USD","SG9999015978.USD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0965509283.SGD","LU1003077747.HKD","LU2468319806.SGD","BK4533","IE00BN8TJ469.HKD","LU0689472784.USD","LU0198837287.USD","LU1074936037.SGD","LU0456855351.SGD","LU1057294990.SGD","LU1732799900.SGD","LU2112291526.USD","LU1037948897.HKD","LU0098860793.USD","LU1551013342.USD","LU2237443549.SGD","LU0211328371.USD","LU0661504455.SGD","LU0256863811.USD"],"gpt_icon":0},{"id":"1107664320","title":"艾伯维公司未来十年将斥资1000亿美元投入美国研发及资本开支，涵盖制造业","url":"https://stock-news.laohu8.com/highlight/detail?id=1107664320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107664320?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260770,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将在未来十年内于美国市场投入高达1000亿美元的资金，重点投向研发活动以及资本性支出，其中制造业相关投资亦被纳入这一庞大计划。这一战略部署彰显了公司对强化本土创新能力和生产基础设施的长期承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU1074936037.SGD","LU0882574055.USD","LU2087621335.USD","LU0912757837.SGD","LU1057294990.SGD","LU0234570918.USD","BK4550","LU0310799852.SGD","LU0545039389.USD","LU0553294199.USD","BK4533","BK4559","BK4581","IE00B3PB1722.GBP","LU0122379950.USD","SG9999011175.SGD","LU0456855351.SGD","BK4139","LU0234572021.USD","LU1162221912.USD","LU1989772840.SGD","LU2237443465.HKD","LU0965509101.SGD","IE00B19Z3581.USD","LU0170899867.USD","SG9999015952.SGD","BK4585","LU0211327993.USD","ABBV","LU1037948541.HKD","LU0211328371.USD","LU1093756325.SGD","IE0004445239.USD","LU0861579265.USD","LU1061106388.HKD","SG9999015986.USD","LU0114720955.EUR","LU2133065610.SGD","LU0985320562.USD","IE00BBT3K403.USD","LU0417517546.SGD","IE00BSNM7G36.USD","IE00BVYPNW00.USD","LU0320765646.SGD","LU1023059063.AUD","LU1732799900.SGD","LU1839511570.USD","LU0820561909.HKD","LU0128525929.USD","LU1244550494.USD","LU0029864427.USD","LU1551013425.SGD","BK4588","LU0124676726.USD","LU0689472784.USD","LU2468319806.SGD","LU1291159041.SGD","IE0002141913.USD","SG9999015978.USD","LU1496350502.SGD","LU0203345920.USD","SG9999015945.SGD","LU1496350171.SGD","LU0098860793.USD","IE00B19Z3B42.SGD","LU1929549753.HKD","LU2089984988.USD","IE00BLSP4452.SGD","IE00B42XCP33.USD","LU0738911758.USD","LU1267930490.SGD","LU1934455277.USD","LU0289739699.SGD","LU0310800379.SGD","LU2237443622.USD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU2237443382.USD","LU1983299246.USD","LU2237443978.SGD","LU0943347566.SGD","LU1003077747.HKD","LU0708994859.HKD","LU2089283258.USD","LU0058720904.USD","LU1244550577.SGD","LU1430594728.SGD","LU1585245621.USD","SG9999003800.SGD","LU0158827948.USD","IE00B2B36J28.USD","LU1244550221.USD","LU2347655156.SGD","IE00BVYPNV92.GBP","LU0256863902.USD","LU1718418525.SGD","LU2112291526.USD","LU2237443895.HKD","LU1989771016.USD","LU1037948897.HKD","LU2129689514.USD","IE0002270589.USD","LU2237443549.SGD","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","BK4566","LU1732800096.USD","LU0795875169.SGD","LU1934455194.USD","LU2023251221.USD","LU0661504455.SGD","LU0689626769.HKD","IE00B4R5TH58.HKD","LU1093756168.USD","LU1989772923.USD","IE00BJT1NW94.SGD","LU2129689605.HKD","IE0009355771.USD","LU0820561818.USD","LU0256863811.USD","LU0795875086.SGD","BK4534","IE00BGHQF631.EUR","LU0965508806.USD","LU0949170772.SGD","LU0198837287.USD","SG9999001440.SGD","LU1551013342.USD","LU0203347892.USD","LU1934455863.HKD","LU0432979614.USD","IE00BDGV0183.EUR","LU2129689431.USD","LU2089284900.SGD","LU1267930573.SGD"],"gpt_icon":0},{"id":"1156023584","title":"艾伯维公司：将通过Trumprx平台为医疗补助计划提供低价药品，并扩大面向患者的可负担直接治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1156023584","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156023584?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:32","pubTimestamp":1768260766,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，将通过其Trumprx平台为医疗补助计划参与者提供低价药品，同时扩大面向患者的可负担直接治疗方案。这一举措旨在提升药品可及性，让更多患者能够以合理价格获得所需治疗。\n通过Trumprx平台，艾伯维将优化药品供应流程，实现从药企到患者的直接服务模式。该战略不仅涵盖价格优惠，还将简化购药流程，为医疗补助计划受益者及自费患者提供更便捷的用药体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","IE00B2B36J28.USD","IE0009355771.USD","LU2129689431.USD","LU1267930573.SGD","LU1839511570.USD","LU0256863902.USD","SG9999003800.SGD","SG9999015952.SGD","IE00BLSP4452.SGD","LU0965509010.AUD","LU0912757837.SGD","LU1496350502.SGD","LU1718418525.SGD","BK4581","LU0689472784.USD","LU0203347892.USD","LU2237443465.HKD","LU0128525929.USD","IE00B3PB1722.GBP","BK4533","LU0310800379.SGD","LU1551013425.SGD","LU1244550577.SGD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU1037948897.HKD","LU1244550221.USD","LU2237443622.USD","LU2023251221.USD","BK4550","IE00BN8TJ469.HKD","IE0002270589.USD","LU1093756325.SGD","IE00B19Z3B42.SGD","BK4559","LU0417517546.SGD","LU1585245621.USD","LU0553294199.USD","LU0114720955.EUR","LU0211327993.USD","LU1934455194.USD","LU0795875169.SGD","LU1037948541.HKD","LU2089284900.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0861579265.USD","LU1061106388.HKD","LU0965509283.SGD","LU0965508806.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU0985320562.USD","IE00BBT3K403.USD","SG9999015945.SGD","LU0124676726.USD","BK4139","LU0965509101.SGD","LU2237443549.SGD","LU2237443895.HKD","LU2237443978.SGD","LU1732800096.USD","LU0738911758.USD","SG9999011175.SGD","LU0882574055.USD","LU1934455863.HKD","BK4534","LU1093756168.USD","LU0708994859.HKD","LU0234572021.USD","IE00BLSP4239.USD","LU1291159041.SGD","LU0949170772.SGD","LU0545039389.USD","LU1551013342.USD","LU2089984988.USD","LU2129689605.HKD","LU0198837287.USD","LU1003077747.HKD","IE00BVYPNV92.GBP","LU2347655156.SGD","LU0795875086.SGD","LU1983299246.USD","LU1934455277.USD","LU0234570918.USD","LU0820561909.HKD","IE00B42XCP33.USD","SG9999015986.USD","LU1074936037.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0820561818.USD","LU2468319806.SGD","LU0432979614.USD","LU0203345920.USD","LU1496350171.SGD","LU1023059063.AUD","LU0320765646.SGD","BK4588","IE00BSNM7G36.USD","LU1244550494.USD","LU0211328371.USD","IE00B4R5TH58.HKD","LU0170899867.USD","BK4585","LU1929549753.HKD","LU1989771016.USD","SG9999001440.SGD","LU2237443382.USD","LU1989772923.USD","LU0029864427.USD","LU2089283258.USD","LU0289739699.SGD","BK4566","IE00BVYPNW00.USD","LU0058720904.USD","LU0158827948.USD","LU0098860793.USD","LU2133065610.SGD","LU0310799852.SGD","LU2129689514.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1267930490.SGD","SG9999015978.USD","LU0689626769.HKD","LU1162221912.USD","LU0122379950.USD","LU0943347566.SGD","ABBV","IE00BGHQF631.EUR","LU1989772840.SGD","IE00BDGV0183.EUR","LU0661504455.SGD","LU1732799900.SGD"],"gpt_icon":0},{"id":"1107559382","title":"艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1107559382","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107559382?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:33","pubTimestamp":1768221217,"startTime":"0","endTime":"0","summary":"根据最新合作协议，荣昌生物（Remegen）有资格从艾伯维（AbbVie）获得累计最高达49.5亿美元的款项。这笔巨额资金将涵盖药物研发、监管审批及商业化等多个阶段的里程碑奖励。\n该合作凸显了国际制药巨头对中国生物科技企业创新能力的认可。分段式的付款机制既保障了研发进程的可控性，也为双方创造了共赢的商业前景。随着合作项目的推进，荣昌生物有望通过达成特定技术指标和销售目标激活相应阶段的付款。\n此次交易金额创下中国生物科技企业对外授权合作的新纪录，预示着国内创新药企在全球医药产业链中的地位正在快速提升。双方未透露具体适应症细节，但市场预期该合作可能涉及肿瘤或自身免疫疾病领域的前沿疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU0203345920.USD","LU2089984988.USD","LU1093756325.SGD","LU0545039389.USD","LU2087621335.USD","LU0965509101.SGD","LU0882574055.USD","LU1732800096.USD","LU0058720904.USD","LU1934455863.HKD","LU2237443549.SGD","IE00BN8TJ469.HKD","LU1732799900.SGD","LU0861579265.USD","LU1718418525.SGD","LU2133065610.SGD","LU0708994859.HKD","LU1064130708.USD","IE00BLSP4452.SGD","LU0124676726.USD","LU1267930573.SGD","IE00BLSP4239.USD","LU1839511570.USD","LU0234570918.USD","LU2237443622.USD","SG9999015952.SGD","SG9999011175.SGD","LU0820561818.USD","LU0795875086.SGD","SG9999015986.USD","LU2488822045.USD","IE00B3PB1722.GBP","LU1061106388.HKD","LU2237443978.SGD","LU2468319806.SGD","LU1162221912.USD","LU2347655156.SGD","IE00BBT3K403.USD","IE00B42XCP33.USD","LU0158827948.USD","IE0002270589.USD","LU0203347892.USD","BK4585","LU0661504455.SGD","LU2023251221.USD","LU0098860793.USD","LU0029864427.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU1244550494.USD","LU1551013342.USD","LU0114720955.EUR","BK4566","LU1934455277.USD","LU0689626769.HKD","LU1551013425.SGD","BK4559","LU1989772840.SGD","688331","LU0256863902.USD","LU1496350171.SGD","IE00BGHQF631.EUR","SG9999015945.SGD","LU0985320562.USD","LU2129689514.USD","IE00BDGV0183.EUR","LU1430594728.SGD","LU2089283258.USD","LU1244550221.USD","LU2129689605.HKD","LU0211328371.USD","SG9999015978.USD","LU0943347566.SGD","LU0198837287.USD","LU2237443895.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0949170772.SGD","BK4588","LU0417517546.SGD","IE0002141913.USD","LU0965509283.SGD","LU1496350502.SGD","LU0965509010.AUD","LU1003077747.HKD","LU1023059063.AUD","LU1983299246.USD","IE0009355771.USD","LU0912757837.SGD","LU0320765646.SGD","LU2112291526.USD","IE00BVYPNV92.GBP","LU0122379950.USD","SG9999001440.SGD","LU0432979614.USD","LU0738911758.USD","LU0820561909.HKD","LU2089284900.SGD","BK4533","LU2237443465.HKD","LU2237443382.USD","LU1267930490.SGD","LU1929549753.HKD","IE00BVYPNW00.USD","LU0289739699.SGD","LU1934455194.USD","LU1291159041.SGD","LU2129689431.USD","LU0234572021.USD","LU1989772923.USD","LU0256863811.USD","BK4139","IE00B19Z3B42.SGD","IE0004445239.USD","LU0310800379.SGD","LU0553294199.USD","BK0239","LU1093756168.USD","LU0689472784.USD","SG9999003800.SGD","BK4550","LU0456855351.SGD","LU2148510915.USD","ABBV","LU1037948541.HKD","LU1989771016.USD","LU1064131003.USD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU1057294990.SGD","LU1074936037.SGD","BK4581","IE00BJT1NW94.SGD","LU0310799852.SGD","LU0211327993.USD","IE00B19Z3581.USD","BK4534","LU1244550577.SGD","LU0795875169.SGD","LU0965508806.USD","LU0128525929.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"1140361953","title":"艾伯维收购亚利桑那州生产设施，持续强化美国本土制造能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1140361953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140361953?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215713,"startTime":"0","endTime":"0","summary":"艾伯维公司近日宣布，将收购位于亚利桑那州的一处生产设施。这一战略举措旨在进一步增强其在美国本土的制造实力，为未来的产品供应提供有力保障。收购完成后，该设施将整合进艾伯维现有的生产网络，提升其在关键治疗领域的产能与灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124676726.USD","LU1551013342.USD","LU0432979614.USD","LU2089284900.SGD","LU0417517546.SGD","IE0004445239.USD","LU0545039389.USD","BK4566","LU2089283258.USD","SG9999003800.SGD","IE00BJJMRZ35.SGD","IE00B42XCP33.USD","LU2089984988.USD","LU1291159041.SGD","LU0170899867.USD","IE00B64QTZ34.USD","SG9999001440.SGD","LU2237443465.HKD","LU0234572021.USD","LU1718418525.SGD","IE00BGHQF631.EUR","SG9999011175.SGD","LU1003077747.HKD","LU0345774631.USD","LU0203345920.USD","IE00BDGV0183.EUR","IE00BBT3K403.USD","LU0985320562.USD","LU1496350502.SGD","LU1989772840.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU2468319806.SGD","LU2237443549.SGD","LU0689626769.HKD","LU1244550577.SGD","LU0122379950.USD","LU0689472784.USD","LU0820561818.USD","LU1162221912.USD","LU0128525929.USD","LU1839511570.USD","LU0106261612.USD","LU1057294990.SGD","LU0158827948.USD","LU2237443978.SGD","SG9999015986.USD","LU2112291526.USD","LU0943347566.SGD","LU1934455277.USD","IE00BSNM7G36.USD","WST","LU0310799852.SGD","LU2129689431.USD","LU0256863811.USD","LU2347655156.SGD","IE00BN8TJ469.HKD","LU1430594728.SGD","LU1244550494.USD","IE00B19Z3B42.SGD","LU0912757837.SGD","BK4534","LU0965509101.SGD","LU2023251221.USD","LU2087621335.USD","BK4550","LU0553294199.USD","LU0965509010.AUD","SG9999015945.SGD","ABBV","LU1244550221.USD","BK4559","LU0738911758.USD","SG9999015952.SGD","LU0203347892.USD","LU0289739699.SGD","LU2129689514.USD","IE00B19Z3581.USD","LU0211327993.USD","LU0882574055.USD","LU0795875169.SGD","IE00BVYPNW00.USD","LU0012050646.USD","LU1496350171.SGD","LU0029864427.USD","LU1551013425.SGD","LU0708994859.HKD","LU0198837287.USD","LU0965508806.USD","BK4504","IE00BJT1NW94.SGD","LU0310800379.SGD","IE00BLSP4239.USD","LU1074936037.SGD","BK4139","LU2129689605.HKD","IE00BVYPNV92.GBP","BK4585","IE00BYQQ9H92.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1037948541.HKD","LU0820561909.HKD","LU2237443382.USD","LU1934455194.USD","IE0002270589.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU1061106388.HKD","LU1093756168.USD","LU1732799900.SGD","LU2133065610.SGD","SG9999015978.USD","IE00B3PB1722.GBP","LU0661504455.SGD","LU0861579265.USD","LU1989772923.USD","LU1934455863.HKD","LU1093756325.SGD","BK4588","BK4533","LU0234570918.USD","LU0965509283.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","LU0256863902.USD","IE00BFXG0V08.USD","BK4121","LU1037948897.HKD","LU0098860793.USD","LU0345774391.USD","LU2237443622.USD","LU0795875086.SGD","LU0320765646.SGD","BK4567","LU0114720955.EUR","LU1732800096.USD","IE0009355771.USD","LU1267930490.SGD","BK4581","LU0211328371.USD","LU1929549753.HKD","LU2237443895.HKD","LU1267930573.SGD","LU0949170772.SGD","IE0002141913.USD","LU1989771016.USD","LU1585245621.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.0107},{"period":"3month","weight":-0.0463},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1686},{"period":"ytd","weight":-0.0265}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.785714,"avgChangeRate":0.035994},{"month":3,"riseRate":0.769231,"avgChangeRate":0.006022},{"month":4,"riseRate":0.615385,"avgChangeRate":0.009221},{"month":5,"riseRate":0.615385,"avgChangeRate":0.002163},{"month":6,"riseRate":0.461538,"avgChangeRate":0.008788},{"month":7,"riseRate":0.538462,"avgChangeRate":0.01232},{"month":8,"riseRate":0.538462,"avgChangeRate":0.007409},{"month":9,"riseRate":0.538462,"avgChangeRate":0.014941},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}